Gore Receives FDA Approval for the GORE® EXCLUDER® Conformable AAA Endoprosthesis with ACTIVE CONTROL System
The innovative device and delivery system combine proven conformability with new levels of control.
Jan 6, 2021
W. L. GORE & ASSOCIATES ANNOUNCES ENCOURAGING SIX-MONTH RESULTS WITH ITS NOVEL BIOSYNTHETIC TISSUE VALVE
At the American Heart Association Virtual Scientific Sessions 2020.
Nov 18, 2020
W. L. Gore & Associates enhances GORE® VIABAHN® Endoprosthesis portfolio with lower profile delivery
Improvements to large diameter devices include accessiblity through smaller sheaths while providing enhanced visualization under fluoroscopy
Sep 22, 2020
W. L. Gore & Associates Marks 20 Years of Improving and Extending Life for Patients with Liver Cirrhosis Complications
As liver disease prevalence grows worldwide, earlier TIPS intervention with the GORE® VIATORR® TIPS Endoprosthesis has proven to increase survival and to reduce complications of liver cirrhosis over conventional therapies.1
Aug 25, 2020
COVID-19: Our Current Path Forward
May 11, 2020
GORE Clinical Study Receives JVIR Editor’s Award For Outstanding Clinical Research Paper For 2019 From Journal of Vascular and Interventional Radiology
Analysis of the Gore REVISE Clinical Study data examined reinterventions and associated costs to maintain dialysis access in thrombosed and stenotic circuits.
May 1, 2020
Gore Receives CE Mark for the GORE® CARDIOFORM ASD Occluder for the Treatment of Atrial Septal Defects in Europe
CE Mark supported by data from the Gore ASSURED Clinical Study, demonstrating 100 percent closure success
Oct 2, 2019
W. L. Gore & Associates Hires John Laschinger, M.D., as Medical Products Division’s Cardiac Chief Medical Advisor
Gore furthers its commitment to patient-centered cardiac innovation
Sep 26, 2019